Summary.-Sixteen chronic myeloid leukaemia (CML) patients in remission were tested with solubilized membrane antigens from CML leukaemic cells, CML blasts, AML blasts and ALL blasts for cellular immunity in vitro by lymphocyte transformation (LT) and leucocyte migration inhibition (LMI) assays. Twelve CML patients in remission were tested with allogeneic PHA-transformed normal lymphoblasts. As controls, peripheral-blood leucocytes from 9 healthy persons were tested with the same antigen preparations. It was seen that 8/16 (50 %) CML patients responded to CML antigens by both LT and LMI assays, while 5/16 (31o0) patients reacted to CML blasts and 440o (7/16) patients reacted to AML blast antigens. It was interesting to note that 5/11 (45°/,) CML patients reacted to ALL blast antigens by both assays. One out of 12 patients reacted to PHA-transformed lymphoblasts. None of the healthy controls reacted to leukaemia-associated antigens. The results suggest the sharing of antigens between myeloid leukaemic cells, myeloid blasts and lymphoid blasts.
CELLULAR senisitization to leukaemiaassociated antigens in patients suffering from acute leukaemias has been well documented (Freedman & Kourilsky, 1969; Levanthal et al., 1972; Santos et al., 1973; Anderson et al., 1974) . The degree of cellular immunity has been correlated with the clinical stage of the disease (Giutterman et al., 1973; Char et al., 1973) . In our earlier studies we reported that chronic myeloid leukaemia (CML) patients in remission show cell-mediated immunity to solubilized autochthonous and allogeneic leukaemic cell-membrane antigens when tested by the leucocyte migration inhibition (LMI) assay (Gangal et al., 1976) . We have also attempted to follow up a small group of patients through 2-3 cycles of remissions and relapses and tried to correlate the leukaemia-associat,ed reactivity with the prognosis of the disease (Grangal et al., 1977) .
One of the major features of CML is that at the terminal stage of blastic crisis, the disease clinically resembles acute myeloid leukaemia (AML) (WVintrobe, 1974) . Sometimes at this stage the clinical and haematological picture is such that it is difficult to distinguish myeloblasts from lymphoblasts (Wintrobe, 1974; Boggs, 1974 12/39 (31%) 5/16 (310o) :394
DISCUSSION
Our previous studies showed that CML patients in remission were sensitized to leukaemia-associated antigens (Gangal et al., 1976 (Gangal et al., , 1977 . Since most, of the CML patients eventually enter into blastic crisis, and at that stage present, a clinical picture simnilar to AML, it was thought essential to study the reactivity of CML patients to CML and AML blast antigens. ALL antigens were also included in the studies as lymphoid and myeloid blasts are often morphologically indistinguishable and it has been suggested before that anitisera to leukaemic cells cross-reacted with myeloid and lvmphoid blasts (XWhitson et al., 1976; Staveni et al., 1977 (WN; hitson et al., 1976; Zighelboim et al., 1977; Staven et al., 1977; Drew et al., 1977; Mohankumar et al., 1978; Roberts & Greaves, 1978 The reactivities revealed in the present stu(lies thus suggest the presence of crossreacting antigens shared by immature myeloid cells, myeloid and lymphoid leukaemic blasts and, to some extent, normal lymphoblasts. It is possible that these reactivities may be reflecting sensitization of CML patients to antigens of immature cells shared with cells of myeloid and lymphoid lineages rather than the true letukaemia-specific sensitization.
